Literature DB >> 31540697

Incidence of PKAN determined by bioinformatic and population-based analysis of ~140,000 humans.

Daniel Brezavar1, Penelope E Bonnen2.   

Abstract

Panthothenate kinase-associated neurodegeneration (PKAN, OMIM 234200), is an inborn is an autosomal recessive inborn error of metabolism caused by pathogenic variants in PANK2. PANK2 encodes the enzyme pantothenate kinase 2 (EC 2.7.1.33), an essential regulatory enzyme in CoA biosynthesis. Clinical presentation includes dystonia, rigidity, bradykinesia, dysarthria, pigmentary retinopathy and dementia with variable age of onset ranging from childhood to adulthood. In order to provide an accurate incidence estimate of PKAN, we conducted a systematic review of the literature and databases for pathogenic mutations and constructed a bioinformatic profile for pathogenic missense variants in PANK2. We then studied the gnomAD cohort of ~140,000 unrelated adults from global populations to determine the allele frequency of the variants in PANK2 reported pathogenic for PKAN and for those additional variants identified in gnomAD that met bioinformatics criteria for being potentially pathogenic. Incidence was estimated based on three different models using the allele frequencies of pathogenic PKAN variants with or without those bioinformatically determined to be potentially pathogenic. Disease incidence calculations showed PKAN incidence ranging from 1:396,006 in Europeans, 1:1,526,982 in Africans, 1:480,826 in Latino, 1:523,551 in East Asians and 1:531,118 in South Asians. These results indicate PKAN is expected to occur in approximately 2 of every 1 million live births globally outside of Africa, and has a much lower incidence 1 in 1.5 million live births in the African population.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Dystonia; Eye of the tiger; Incidence; Movement disorder; NBIA; PANK2; PKAN; Population genetics; Retinopathy; Variant prediction

Mesh:

Substances:

Year:  2019        PMID: 31540697     DOI: 10.1016/j.ymgme.2019.09.002

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  4 in total

1.  Pilot trial on the efficacy and safety of pantethine in children with pantothenate kinase-associated neurodegeneration: a single-arm, open-label study.

Authors:  Xuting Chang; Jie Zhang; Yuwu Jiang; Bufan Yao; Jingmin Wang; Ye Wu
Journal:  Orphanet J Rare Dis       Date:  2020-09-14       Impact factor: 4.123

2.  Lifetime risk of autosomal recessive mitochondrial disorders calculated from genetic databases.

Authors:  Jing Tan; Matias Wagner; Sarah L Stenton; Tim M Strom; Saskia B Wortmann; Holger Prokisch; Thomas Meitinger; Konrad Oexle; Thomas Klopstock
Journal:  EBioMedicine       Date:  2020-04-16       Impact factor: 8.143

3.  Clinical and Molecular Correlates of Abnormal Changes in the Cerebellum and Globus Pallidus in Fragile X Premutation.

Authors:  Jun Yi Wang; Jim Grigsby; Diego Placido; Hongjiang Wei; Flora Tassone; Kyoungmi Kim; David Hessl; Susan M Rivera; Randi J Hagerman
Journal:  Front Neurol       Date:  2022-02-08       Impact factor: 4.003

4.  Genetic mutation spectrum of pantothenate kinase-associated neurodegeneration expanded by breakpoint sequencing in pantothenate kinase 2 gene.

Authors:  Dahae Yang; Sanghyun Cho; Sung Im Cho; Manjin Kim; Moon-Woo Seong; Sung Sup Park
Journal:  Orphanet J Rare Dis       Date:  2022-03-04       Impact factor: 4.123

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.